Logo image of CELU

CELULARITY INC-A (CELU) Stock Fundamental Analysis

USA - NASDAQ:CELU - US1511902041 - Common Stock

1.95 USD
-0.05 (-2.5%)
Last: 10/29/2025, 9:42:53 AM
Fundamental Rating

2

Overall CELU gets a fundamental rating of 2 out of 10. We evaluated CELU against 534 industry peers in the Biotechnology industry. CELU may be in some trouble as it scores bad on both profitability and health. CELU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CELU had negative earnings in the past year.
CELU had a negative operating cash flow in the past year.
CELU had negative earnings in 4 of the past 5 years.
In the past 5 years CELU always reported negative operating cash flow.
CELU Yearly Net Income VS EBIT VS OCF VS FCFCELU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

CELU has a Return On Assets (-61.30%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -61.3%
ROE N/A
ROIC N/A
ROA(3y)-58.77%
ROA(5y)-40.28%
ROE(3y)-375.51%
ROE(5y)-245.63%
ROIC(3y)N/A
ROIC(5y)N/A
CELU Yearly ROA, ROE, ROICCELU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

CELU has a Gross Margin of 55.10%. This is in the better half of the industry: CELU outperforms 76.97% of its industry peers.
In the last couple of years the Gross Margin of CELU has grown nicely.
CELU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.74%
GM growth 5YN/A
CELU Yearly Profit, Operating, Gross MarginsCELU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

CELU does not have a ROIC to compare to the WACC, probably because it is not profitable.
CELU has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CELU has been increased compared to 5 years ago.
CELU has a worse debt/assets ratio than last year.
CELU Yearly Shares OutstandingCELU Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CELU Yearly Total Debt VS Total AssetsCELU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

CELU has an Altman-Z score of -12.21. This is a bad value and indicates that CELU is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -12.21, CELU is not doing good in the industry: 76.59% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.21
ROIC/WACCN/A
WACC6.3%
CELU Yearly LT Debt VS Equity VS FCFCELU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 0.25 indicates that CELU may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.25, CELU is doing worse than 94.76% of the companies in the same industry.
A Quick Ratio of 0.19 indicates that CELU may have some problems paying its short term obligations.
CELU's Quick ratio of 0.19 is on the low side compared to the rest of the industry. CELU is outperformed by 95.51% of its industry peers.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.19
CELU Yearly Current Assets VS Current LiabilitesCELU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.65% over the past year.
The Revenue has been growing slightly by 4.45% in the past year.
The Revenue has been growing by 36.47% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)44.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-243.92%
Revenue 1Y (TTM)4.45%
Revenue growth 3Y36.47%
Revenue growth 5YN/A
Sales Q2Q%-52.64%

3.2 Future

The Earnings Per Share is expected to decrease by -119.65% on average over the next years. This is quite bad
The Revenue is expected to grow by 98.27% on average over the next years. This is a very strong growth
EPS Next Y-752.63%
EPS Next 2Y-119.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year27.37%
Revenue Next 2Y49.72%
Revenue Next 3Y144.15%
Revenue Next 5Y98.27%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CELU Yearly Revenue VS EstimatesCELU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CELU Yearly EPS VS EstimatesCELU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CELU. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELU Price Earnings VS Forward Price EarningsCELU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELU Per share dataCELU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as CELU's earnings are expected to decrease with -119.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-119.65%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CELU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELULARITY INC-A

NASDAQ:CELU (10/29/2025, 9:42:53 AM)

1.95

-0.05 (-2.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-14 2025-10-14
Earnings (Next)12-04 2025-12-04
Inst Owners13.1%
Inst Owner Change2.05%
Ins Owners11.65%
Ins Owner Change0%
Market Cap52.05M
Revenue(TTM)44.59M
Net Income(TTM)-73731000
Analysts82.86
Price Target6.12 (213.85%)
Short Float %4.27%
Short Ratio4.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)140%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1057.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-61.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.17
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.19
EYN/A
EPS(NY)-2.8
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS1.67
BVpS-0.96
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.1%
FCFM N/A
ROA(3y)-58.77%
ROA(5y)-40.28%
ROE(3y)-375.51%
ROE(5y)-245.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.74%
GM growth 5YN/A
F-Score3
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.19
Altman-Z -12.21
F-Score3
WACC6.3%
ROIC/WACCN/A
Cap/Depr(3y)39.96%
Cap/Depr(5y)N/A
Cap/Sales(3y)16.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-243.92%
EPS Next Y-752.63%
EPS Next 2Y-119.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.45%
Revenue growth 3Y36.47%
Revenue growth 5YN/A
Sales Q2Q%-52.64%
Revenue Next Year27.37%
Revenue Next 2Y49.72%
Revenue Next 3Y144.15%
Revenue Next 5Y98.27%
EBIT growth 1Y-5.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y95.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.28%
OCF growth 3YN/A
OCF growth 5YN/A

CELULARITY INC-A / CELU FAQ

What is the ChartMill fundamental rating of CELULARITY INC-A (CELU) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CELU.


Can you provide the valuation status for CELULARITY INC-A?

ChartMill assigns a valuation rating of 0 / 10 to CELULARITY INC-A (CELU). This can be considered as Overvalued.


How profitable is CELULARITY INC-A (CELU) stock?

CELULARITY INC-A (CELU) has a profitability rating of 1 / 10.


Can you provide the financial health for CELU stock?

The financial health rating of CELULARITY INC-A (CELU) is 0 / 10.


What is the expected EPS growth for CELULARITY INC-A (CELU) stock?

The Earnings per Share (EPS) of CELULARITY INC-A (CELU) is expected to decline by -752.63% in the next year.